Get the Stockscreener App
4.44
0.45%
+0.02
After Hours:
4.44
Applied Therapeutics Inc stock is currently priced at $4.44, with a 24-hour trading volume of 565.30K.
It has seen a +0.45% increased in the last 24 hours and a -29.86% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $4.37 pivot point. If it approaches the $4.51 resistance level, significant changes may occur.
Previous Close:
$4.42
Open:
$4.42
24h Volume:
565.30K
Market Cap:
$507.23M
Revenue:
-
Net Income/Loss:
$-119.76M
P/E Ratio:
-4.00
EPS:
-1.11
Net Cash Flow:
$-55.17M
1W Performance:
+3.02%
1M Performance:
-29.86%
6M Performance:
+91.38%
1Y Performance:
+146.67%
1D Range:
$4.38
$4.68
52W Range:
$1.18
$9.39
Applied Therapeutics Inc Stock (APLT) Company Profile
Name
Applied Therapeutics Inc
Sector
Industry
Phone
212 220 9226
Address
545 Fifth Avenue, Suite 1400, New York, NY
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-04-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-27-21 | Downgrade | Goldman | Neutral → Sell |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Oct-08-20 | Initiated | Truist | Buy |
| Apr-22-20 | Initiated | Goldman | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jun-10-19 | Initiated | Citigroup | Buy |
| Jun-10-19 | Initiated | Cowen | Outperform |
| Jun-10-19 | Initiated | Robert W. Baird | Outperform |
View All
Applied Therapeutics Inc Stock (APLT) Latest News
G1 Therapeutics (GTHX) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer
GlobeNewswire Inc.
Why Doma Holdings Shares Are Trading Higher By Around 34%; Here Are 20 Stocks Moving Premarket
Benzinga
Oxford Industries Posts Weak Results, Joins Applied Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Benzinga
Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia
GlobeNewswire Inc.
Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why
Zacks Investment Research
Applied Therapeutics Inc Stock (APLT) Financials Data
Applied Therapeutics Inc (APLT) Net Income 2024
APLT net income (TTM) was -$119.76 million for the quarter ending December 31, 2023, a -45.15% decrease year-over-year.
Applied Therapeutics Inc (APLT) Cash Flow 2024
APLT recorded a free cash flow (TTM) of -$55.17 million for the quarter ending December 31, 2023, a +29.35% increase year-over-year.
Applied Therapeutics Inc (APLT) Earnings per Share 2024
APLT earnings per share (TTM) was -$1.35 for the quarter ending December 31, 2023, a +43.75% growth year-over-year.
About Applied Therapeutics Inc
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the treatment of phosphomannomutase enzyme-CDG. The company also develops AT-001 that is in phase III clinical trials for treating diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy. Its preclinical stage products include AT-003 for the treatment diabetic retinopathy; AT-104, a PI3K inhibitor for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.
3.18%
Cap:
|
Volume (24h):